JP2008517900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008517900A5 JP2008517900A5 JP2007537422A JP2007537422A JP2008517900A5 JP 2008517900 A5 JP2008517900 A5 JP 2008517900A5 JP 2007537422 A JP2007537422 A JP 2007537422A JP 2007537422 A JP2007537422 A JP 2007537422A JP 2008517900 A5 JP2008517900 A5 JP 2008517900A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- agent
- isd
- seq
- staphylococcus aureus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62192104P | 2004-10-25 | 2004-10-25 | |
| PCT/IB2005/004126 WO2006059247A2 (en) | 2004-10-25 | 2005-10-25 | VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008517900A JP2008517900A (ja) | 2008-05-29 |
| JP2008517900A5 true JP2008517900A5 (https=) | 2008-12-18 |
Family
ID=36565416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007537422A Pending JP2008517900A (ja) | 2004-10-25 | 2005-10-25 | スタフィロコッカス−アウレウスＩｓｄたんぱく質ベースの抗感染薬 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1812066A4 (https=) |
| JP (1) | JP2008517900A (https=) |
| KR (1) | KR20070085457A (https=) |
| AU (1) | AU2005310981A1 (https=) |
| CA (1) | CA2581746A1 (https=) |
| WO (1) | WO2006059247A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2586125T3 (es) | 2005-02-14 | 2016-10-11 | Epitopix, Llc | Polipéptidos de Staphylococcus aureus y métodos de uso |
| US20090317421A1 (en) * | 2006-01-18 | 2009-12-24 | Dominique Missiakas | Compositions and methods related to staphylococcal bacterium proteins |
| MY148405A (en) | 2006-03-30 | 2013-04-30 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| CA2667788A1 (en) * | 2006-10-30 | 2008-12-18 | The University Of Western Ontario | Staphylococcus aureus specific anti-infectives |
| EP2185190B1 (en) | 2007-08-31 | 2015-06-24 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
| WO2010014304A1 (en) | 2008-07-29 | 2010-02-04 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
| NZ614557A (en) | 2009-03-23 | 2015-03-27 | Epitopix Llc | Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use |
| ES2784957T3 (es) | 2009-04-03 | 2020-10-02 | Univ Chicago | Composiciones y métodos relacionados con variantes de la proteína A (SPA) |
| GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| JP6002128B2 (ja) | 2010-07-02 | 2016-10-05 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | プロテインＡ（ＳｐＡ）変種に関連する組成物および方法 |
| US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
| SG11201507141SA (en) * | 2013-03-15 | 2015-10-29 | Techulon Inc | Antisense molecules for treatment of staphylococcus aureus infection |
| US9834768B2 (en) | 2014-12-31 | 2017-12-05 | Korea Advanced Institute Of Science And Technology | Effective method for specific gene silencing using artificial small RNA |
| MX2021013833A (es) | 2019-05-14 | 2022-03-17 | Univ Chicago | Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa). |
| WO2021051136A1 (en) | 2019-09-13 | 2021-03-18 | The University Of Chicago | Methods and compositions for treating staphylococcal infections |
| CN120943954B (zh) * | 2025-10-20 | 2026-02-06 | 重庆原伦生物科技有限公司 | 抗金黄色葡萄球菌IsdB抗体的制备及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002306849A1 (en) * | 2001-03-21 | 2002-10-08 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
| JP4424984B2 (ja) * | 2001-06-15 | 2010-03-03 | インヒビテックス インコーポレーテッド | コアグラーゼ陰性ブドウ球菌および黄色ブドウ球菌由来の表面蛋白質を認識する、交差反応性モノクローナルおよびポリクローナル抗体 |
| EP1412379B1 (en) * | 2001-08-02 | 2012-01-25 | The University Of Sheffield | Vaccine |
| ATE457737T1 (de) * | 2003-07-24 | 2010-03-15 | Merck & Co Inc | Polypeptide zur induktion einer schützenden immunantwort gegen staphylococcus aureus |
| KR20070058631A (ko) * | 2004-09-22 | 2007-06-08 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 조성물 |
-
2005
- 2005-10-25 EP EP05850805A patent/EP1812066A4/en not_active Withdrawn
- 2005-10-25 CA CA002581746A patent/CA2581746A1/en not_active Abandoned
- 2005-10-25 KR KR1020077011878A patent/KR20070085457A/ko not_active Withdrawn
- 2005-10-25 AU AU2005310981A patent/AU2005310981A1/en not_active Abandoned
- 2005-10-25 JP JP2007537422A patent/JP2008517900A/ja active Pending
- 2005-10-25 WO PCT/IB2005/004126 patent/WO2006059247A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008517900A5 (https=) | ||
| CA2909080C (en) | Methods, uses and compositions of tie2 agonists | |
| JP2008536483A5 (https=) | ||
| JP2002542798A5 (https=) | ||
| JP2008546390A5 (https=) | ||
| JP2006519605A5 (https=) | ||
| RU2012107993A (ru) | Полипептиды porhyromonas gingivalis | |
| JP2012522010A5 (https=) | ||
| JP2010530238A5 (https=) | ||
| AU2019205602A1 (en) | Peptides having protease activity for use in the treatment or prevention of coronavirus infection | |
| JP2009545526A5 (https=) | ||
| US20240218059A1 (en) | TGF-Beta 1 INHIBITORS FOR PREVENTING AND TREATING SARS-COV-2 | |
| WO2015131076A1 (en) | Nlrp6 inflammasome intestinal epithelium mucus secretion | |
| WO2012102793A2 (en) | Mammalian genes involved in toxicity and infection | |
| CA2693717A1 (en) | Immunology treatment for biofilms | |
| Lin et al. | Human cytomegalovirus and Epstein–Barr virus inhibit oral bacteria‐induced macrophage activation and phagocytosis | |
| WO2016079321A1 (en) | Antagonists of setdb2 for use in the therapy of infectious diseases | |
| CN107849106A (zh) | 融合分子 | |
| JP2016520570A (ja) | Ａ型インフルエンザウイルス感染の治療又は予防に使用するためのｐａｒ−４アンタゴニスト | |
| KR20010052244A (ko) | Ｎ-말단 콜린 결합 단백질 ａ 절단물의 아미노산을포함하는 폴리펩티드, 이로부터 유도된 백신 및 이의 용도 | |
| US9125861B2 (en) | PAR2 agonists for use in the treatment or prevention of influenza virus type A infections | |
| Zhao et al. | A broad-spectrum virus-and host-targeting antiviral peptide against SARS-CoV-2 and other respiratory viruses | |
| KR20110005710A (ko) | 변형된 Ｃｐｎ10 및 ＰＲＲ 시그널링 | |
| Guenther et al. | Modulation of lung inflammation by the Epstein-Barr virus protein Zta | |
| JP2009526861A5 (https=) |